QQ客服 官方微博 反馈留言

	Dual inhibition of PKC delta by carfilzomib (CFZ) and ibrutinib results in synergistic activity in rituximab-chemotherapy sensitive and resistant lymphoma pre-clinical models and in primary tumor cells isolated from b-cell lymphoma patients
	Zhang Q., Gu J.J., Guo Y., Klos J., Mavis C., Czuczman M.S., Hernandez-Ilizaliturri F.J.
刊名	Blood
	2015
卷号	126期号:23
ISSN号	0006-4971
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4867125
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhang Q., Gu J.J., Guo Y., Klos J., Mavis C., Czuczman M.S., Hernandez-Ilizaliturri F.J.. Dual inhibition of PKC delta by carfilzomib (CFZ) and ibrutinib results in synergistic activity in rituximab-chemotherapy sensitive and resistant lymphoma pre-clinical models and in primary tumor cells isolated from b-cell lymphoma patients[J]. Blood,2015,126(23).
APA	Zhang Q., Gu J.J., Guo Y., Klos J., Mavis C., Czuczman M.S., Hernandez-Ilizaliturri F.J..(2015).Dual inhibition of PKC delta by carfilzomib (CFZ) and ibrutinib results in synergistic activity in rituximab-chemotherapy sensitive and resistant lymphoma pre-clinical models and in primary tumor cells isolated from b-cell lymphoma patients.Blood,126(23).
MLA	Zhang Q., Gu J.J., Guo Y., Klos J., Mavis C., Czuczman M.S., Hernandez-Ilizaliturri F.J.."Dual inhibition of PKC delta by carfilzomib (CFZ) and ibrutinib results in synergistic activity in rituximab-chemotherapy sensitive and resistant lymphoma pre-clinical models and in primary tumor cells isolated from b-cell lymphoma patients".Blood 126.23(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。